# A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects

> **NCT01239771** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.

## Interventions

- **DRUG:** TC-5214
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01239771
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239771, "A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01239771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*